PDS Biotechnology CorpNASDAQ:PDSB
- LAST PRICE3.2500
- TODAY'S CHANGE (%)0.0500 (1.5625%)
- Bid / Lots3.2500/ 10
- Ask / Lots3.2600/ 6
- Open / Previous Close3.2500 / 3.2000
- Day Range
- 52 Week Range
- Volume277,760
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PDSB |
|---|---|---|
| 09:32 ET | 20369 | 3.2708 |
| 09:34 ET | 4215 | 3.24 |
| 09:36 ET | 6019 | 3.25 |
| 09:39 ET | 7742 | 3.23 |
| 09:41 ET | 20619 | 3.21 |
| 09:43 ET | 600 | 3.21 |
| 09:45 ET | 4479 | 3.21 |
| 09:48 ET | 757 | 3.2 |
| 09:50 ET | 419 | 3.2 |
| 09:52 ET | 3343 | 3.22 |
| 09:54 ET | 929 | 3.24 |
| 09:56 ET | 550 | 3.225 |
| 09:57 ET | 8651 | 3.25 |
| 09:59 ET | 1373 | 3.25 |
| 10:01 ET | 5377 | 3.255 |
| 10:03 ET | 900 | 3.265 |
| 10:06 ET | 650 | 3.26 |
| 10:08 ET | 5931 | 3.25 |
| 10:10 ET | 300 | 3.255 |
| 10:12 ET | 11400 | 3.27 |
| 10:14 ET | 1313 | 3.28 |
| 10:15 ET | 1348 | 3.26 |
| 10:17 ET | 745 | 3.26 |
| 10:19 ET | 220 | 3.25 |
| 10:21 ET | 9825 | 3.25 |
| 10:24 ET | 500 | 3.26 |
| 10:26 ET | 14234 | 3.285 |
| 10:28 ET | 600 | 3.28 |
| 10:30 ET | 5327 | 3.27 |
| 10:32 ET | 6392 | 3.274 |
| 10:33 ET | 200 | 3.27 |
| 10:35 ET | 1209 | 3.26 |
| 10:37 ET | 3100 | 3.25 |
| 10:39 ET | 300 | 3.243 |
| 10:42 ET | 3978 | 3.24 |
| 10:44 ET | 4300 | 3.25 |
| 10:46 ET | 1029 | 3.23 |
| 10:50 ET | 2165 | 3.24 |
| 10:51 ET | 1300 | 3.22 |
| 10:53 ET | 200 | 3.21 |
| 10:55 ET | 2413 | 3.21 |
| 10:57 ET | 9238 | 3.22 |
| 11:00 ET | 600 | 3.21 |
| 11:04 ET | 700 | 3.2 |
| 11:06 ET | 500 | 3.2 |
| 11:08 ET | 536 | 3.1925 |
| 11:11 ET | 100 | 3.19 |
| 11:13 ET | 2540 | 3.21 |
| 11:15 ET | 3853 | 3.22 |
| 11:18 ET | 400 | 3.23 |
| 11:20 ET | 1500 | 3.2258 |
| 11:22 ET | 3062 | 3.24 |
| 11:24 ET | 800 | 3.24 |
| 11:26 ET | 700 | 3.24 |
| 11:27 ET | 4778 | 3.26 |
| 11:29 ET | 300 | 3.27 |
| 11:31 ET | 1000 | 3.265 |
| 11:33 ET | 100 | 3.27 |
| 11:36 ET | 1789 | 3.26 |
| 11:38 ET | 400 | 3.26 |
| 11:40 ET | 1802 | 3.26 |
| 11:42 ET | 100 | 3.26 |
| 11:44 ET | 700 | 3.26 |
| 11:45 ET | 3757 | 3.26 |
| 11:47 ET | 327 | 3.255 |
| 11:49 ET | 300 | 3.26 |
| 11:54 ET | 500 | 3.26 |
| 11:56 ET | 500 | 3.2501 |
| 12:00 ET | 691 | 3.26 |
| 12:02 ET | 8146 | 3.26 |
| 12:03 ET | 600 | 3.27 |
| 12:05 ET | 1100 | 3.2703 |
| 12:07 ET | 2191 | 3.28 |
| 12:09 ET | 4952 | 3.27 |
| 12:12 ET | 600 | 3.26 |
| 12:14 ET | 200 | 3.26 |
| 12:18 ET | 2300 | 3.275 |
| 12:21 ET | 119 | 3.26 |
| 12:23 ET | 100 | 3.26 |
| 12:30 ET | 200 | 3.265 |
| 12:32 ET | 1100 | 3.255 |
| 12:34 ET | 694 | 3.252 |
| 12:36 ET | 318 | 3.25 |
| 12:38 ET | 2709 | 3.265 |
| 12:41 ET | 960 | 3.265 |
| 12:48 ET | 100 | 3.26 |
| 12:50 ET | 600 | 3.26 |
| 12:52 ET | 400 | 3.265 |
| 12:54 ET | 100 | 3.27 |
| 12:56 ET | 500 | 3.2682 |
| 12:57 ET | 3000 | 3.275 |
| 12:59 ET | 100 | 3.275 |
| 01:01 ET | 900 | 3.275 |
| 01:03 ET | 1779 | 3.27 |
| 01:06 ET | 100 | 3.265 |
| 01:08 ET | 1600 | 3.255 |
| 01:10 ET | 3800 | 3.2501 |
| 01:12 ET | 200 | 3.25 |
| 01:14 ET | 500 | 3.25 |
Yesterday
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune(R) HPV in Combination with KEYTRUDA(R) in Recurrent or Metastatic Head and Neck Cancer, from 8:00AM ET on Tuesday Apr 23, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 23, 2024 by Dow Jones
Mar 28, 2024
DJ PDS Biotechnology Price Target Cut to $11.00/Share From $14.00 by B. Riley Securities, from 12:10PM ET on Thursday Mar 28, 2024 by Dow Jones
12:10PM ET on Thursday Mar 28, 2024 by Dow Jones
Mar 27, 2024
DJ PDS Biotechnology Is Maintained at Buy by HC Wainwright & Co., from 10:39AM ET on Wednesday Mar 27, 2024 by Dow Jones
10:39AM ET on Wednesday Mar 27, 2024 by Dow JonesPDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results, from 7:30AM ET on Wednesday Mar 27, 2024 by Dow Jones
7:30AM ET on Wednesday Mar 27, 2024 by Dow JonesPress Release: PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results, from 7:30AM ET on Wednesday Mar 27, 2024 by Dow Jones
7:30AM ET on Wednesday Mar 27, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
PDS Biotechnology Corp | 117.4M | -2.3x | --- |
Nuvectis Pharma Inc | 117.1M | -4.7x | --- |
Relmada Therapeutics Inc | 118.0M | -1.2x | --- |
GlycoMimetics Inc | 118.3M | -3.1x | --- |
X T L Biopharmaceuticals Ltd | 115.3M | -4.9x | --- |
Rezolute Inc | 114.8M | -2.5x | --- |
Company Information
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Contact Information
- Headquarters
- 303A College Road EastPRINCETON, NJ, United States 08540
- Phone
- ---
- Fax
- 908-790-1212
Executives
- Independent Chairman of the Board
- Stephen Glover
- President, Chief Executive Officer, Director
- Frank Bedu-Addo
- Chief Financial Officer
- Lars Boesgaard
- Senior Vice President, General Counsel
- Spencer Brown
- Senior Vice President - Business Development
- Sanjay Zaveri
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $117.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 36.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.76 |
EPS | $-1.39 |
Book Value | $0.79 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
